“…[37][38][39] These risk factors for disease progression are often present at presentation, and may be compounded if further disease progression is allowed to occur. Based on this, the proven efficacy of CXL, 14,18,19,21,22 the higher risk of CXL-related visual loss aged 435 years, 22 and the relative safety of transepithelial treatment, 33,34 we believe that there is a rational argument for transepithelial CXL at presentation for patients r35 years of age with keratometric stage II disease (Figures 2 and 3). 9 For patients over 35 years without other risk factors, the risk of progression is lower (and CXL-related complications higher), so no intervention is required at presentation.…”